14 completed, 4 terminated, 2 active not recruiting, 2 withdrawn. 7 Phase 2, 7 Phase 3, 6 Phase 1, 2 Phase 4, 1 Not applicable.
Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial Colchicine, Interferon-Beta, Aspirin - Coronavirus, Severe Acute Respiratory Syndrome | Phase 3 | Completed | Population Health Research Institute | 6667 | 2020-04-21 | 2024-01-11 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Mechanism of Action of Ocrelizumab in Multiple Sclerosis ocrelizumab - Multiple Sclerosis, Immune System Diseases | Completed | University of Chicago | 30 | 2018-02-23 | 2025-02-21 | |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon - Multiple Sclerosis | Phase 3 | Terminated | Genzyme, a Sanofi Company | 16 | 2017-10-23 | 2026-08-04 |
| Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3), Interferon-beta - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive | Phase 1 | Unknown | Fundació Institut Germans Trias i Pujol | 16 | 2017-07-06 | 2023-07-07 |
| COMparison Between All immunoTherapies for Multiple Sclerosis. Rituximab - Relapsing-remitting Multiple Sclerosis | Completed | Karolinska Institutet | 3526 | 2017-06-02 | 2025-04-20 | |
| Mesenchymal Stem Cells (MSC) for Ovarian Cancer MSC-INFβ, Questionnaires - Ovarian Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 5 | 2016-05-16 | 2019-07-18 |
| Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 8 | 2015-11-06 | 2022-03-22 |
| Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy Interferon Beta, BIIB017 (Peginterferon beta-1a) - Relapsing Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2014-10-01 | 2014-11-17 | |
| Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2013-02-01 | 2017-04-19 |
| Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) MP-424, RBV(24 weeks), IFN beta(24 weeks) - Chronic Hepatitis C(CHC) | Phase 3 | Completed | Tanabe Pharma Corporation | 74 | 2012-12-01 | 2026-01-06 |
| Multiple Sclerosis: Chi3L1 and Treatment Efficacy Interferon-Beta - Multiple Sclerosis | Completed | Central Hospital, Nancy, France | 63 | 2012-01-01 | 2020-03-09 | |
| Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta) - Multiple Sclerosis Relapse | Phase 3 | Terminated | Sanofi | 534 | 2011-01-01 | 2014-06-09 |
| REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients Interferon-beta and human leukocyte Interferon-α - Multiple Sclerosis | Phase 2 | Completed | Melinda Magyari | 10 | 2010-07-01 | 2012-11-30 |
| Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II Interferon Beta - Acute Lung Injury, Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Faron Pharmaceuticals Ltd | 37 | 2009-02-01 | 2015-05-27 |
| A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Cladribine, Placebo, Interferon-beta (IFN-beta) - Multiple Sclerosis | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 172 | 2006-11-30 | 2020-10-12 |
| Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Interferon beta, Methotrexate - Uveitis, Intermediate, Macular Edema | Phase 3 | Completed | Heidelberg University | 19 | 2006-03-01 | 2012-12-03 |
Showing 20 of 24. Sign in to see all of them.
Multiple Sclerosis (10) · Multiple Sclerosis, Relapsing-Remitting (4) · Carcinoma, Merkel Cell (2) · Acute Lung Injury (1) · Adenoviridae Infections (1) · Adrenoleukodystrophy (1) · Astrocytoma (1) · Brain Neoplasms (1) · COVID-19 (1) · Carcinoma, Ovarian Epithelial (1) · Coronavirus Infections (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Hepatitis C, Chronic (1)
Biogen (4) · Fred Hutchinson Cancer Center (2) · Case Comprehensive Cancer Center (1) · Central Hospital, Nancy, France (1) · EMD Serono Research & Development Institute, Inc. (1) · FDA Office of Orphan Products Development (1) · Faron Pharmaceuticals Ltd (1) · Fundació Institut Germans Trias i Pujol (1) · Genzyme, a Sanofi Company (1) · Heidelberg University (1) · Karolinska Institutet (1) · M.D. Anderson Cancer Center (1) · Melinda Magyari (1) · Population Health Research Institute (1) · Sanofi (1)
United States (10) · Russia (4) · United Kingdom (4) · France (3) · Italy (3) · Spain (3) · Brazil (2) · Canada (2) · Colombia (2) · Germany (2) · Sweden (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1)
Aude Chapuis (2) · Alan Davidson, MD (1) · Alessandra Protti, M.D. (1) · Alexander Binning, MD (1) · Amanda L. Olson, MD (1) · Anders Svenningsson, MD, PhD (1) · Andrea Spissu, M.D. (1) · Angelo Ghezzi, M.D. (1) · Anna Fogdell-Hahn, PhD (1) · Annette Langer-Gould, MD, PhD (1) · Antonio Carolei, M D (1) · Arturo Reggio, Prophessor (1) · Claudio Geda, M.D. (1)
PMID 19278300, PMID 24503265, PMID 25877635, PMID 28497489, PMID 30027104, PMID 31501122, PMID 32447743, PMID 34658014, PMID 36228639, PMID 36228641, PMID 37489818, PMID 38744460, PMID 42218617
P30CA015704 (2), 2009 (1), 2015 (1), 2016 (1), 2019 (1), K24CA139052 (1), P30CA043703 (1), R01CA176841 (1)